137 related articles for article (PubMed ID: 10584344)
1. [Progression and prognosis of in situ carcinoma of the bladder treated with BCG].
Arrizabalaga Moreno M; García González JI; Esteban Artiaga R; Castro Pita M; Navarro Sebastián J; Mora Durbán M; Paniagua Andrés P
Actas Urol Esp; 1999 Sep; 23(8):670-80. PubMed ID: 10584344
[TBL] [Abstract][Full Text] [Related]
2. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
3. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
De Berardinis E; Busetto GM; Antonini G; Giovannone R; Gentile V
Int Urol Nephrol; 2011 Dec; 43(4):1047-57. PubMed ID: 21442469
[TBL] [Abstract][Full Text] [Related]
4. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success.
Lebret T; Gaudez F; Hervé JM; Barré P; Lugagne PM; Botto H
Eur Urol; 1998; 34(1):67-72. PubMed ID: 9676417
[TBL] [Abstract][Full Text] [Related]
5. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
[TBL] [Abstract][Full Text] [Related]
6. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours.
Patard JJ; Rodriguez A; Leray E; Rioux-Leclercq N; Guillé F; Lobel B
Eur Urol; 2002 Jun; 41(6):635-41; discussion 642. PubMed ID: 12074781
[TBL] [Abstract][Full Text] [Related]
7. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
8. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
Peyromaure M; Zerbib M
BJU Int; 2004 Jan; 93(1):60-3. PubMed ID: 14678369
[TBL] [Abstract][Full Text] [Related]
9. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
10. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
11. [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
Ruoppolo M; Gozo M; Milesi R; Spina R; Fragapane G
Urologia; 2010; 77 Suppl 17():72-7. PubMed ID: 21308679
[TBL] [Abstract][Full Text] [Related]
12. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder.
Denzinger S; Burger M; Fritsche HM; Bertz S; Hofstädter F; Wieland WF; Hartmann A; Otto W
Scand J Urol Nephrol; 2009; 43(4):282-7. PubMed ID: 19382004
[TBL] [Abstract][Full Text] [Related]
14. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer.
Bono AV; Lovisolo JA; Saredi G
Eur Urol; 2000 Apr; 37(4):478-83. PubMed ID: 10765080
[TBL] [Abstract][Full Text] [Related]
15. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
16. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
19. [T1 G3 bladder tumors: the respective role of BCG and cystectomy].
Pfister C; Landé P; Hervé JM; Barré P; Barbagelatta M; Camey M; Botto H
Prog Urol; 1995 Apr; 5(2):231-7. PubMed ID: 7719369
[TBL] [Abstract][Full Text] [Related]
20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
